Clinical experiment designed to assess clinical efficacy targeting IDH1, IDH2 in human patients. Primary outcome: patient survival and clinical characteristics based on IDH mutation status
A clinical correlative study examining the relationship between IDH1/IDH2 mutation status and patient outcomes in glioma patients. This analysis evaluated whether patients harboring IDH mutations in their tumors had different clinical characteristics and survival outcomes compared to those with wild-type IDH genes. The study assessed genetic and clinical characteristics associated with IDH mutation status and determined that patients with IDH1 or IDH2 mutations had distinctive features and better clinical outcomes. This represents an important translational component of the study, linking the molecular findings to clinically relevant endpoints and potentially identifying IDH mutation status as a prognostic biomarker in glioma patients.
correlation of IDH mutation status with clinical data including survival outcomes and tumor characteristics
differential clinical outcomes between IDH mutant and wild-type patients
statistically significant differences in clinical parameters between mutation groups
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.